Clinical analysis of Nituzumab in the treatment of head and neck squamous cell carcinoma
Objective To investigate the efficacy and safety of nituzumab in the treatment of locally advanced head and neck squamous cell carcinoma(HNSCC).Methods A total of 31 HNSCC patients were treated in the Affiliated Cancer Hospital of Harbin Medical University from March 2021 to January 2022.Among them,there were 30 males and 1 female,aged 43-84 years with an average age of 63.2 years.Imaging and tissue immunological tests showed HNSCC in all patients,EGFR was positive(+),and liver and kidney function were normal.31 patients were given targeted therapy with nituzumab at a single dose of 200-400 mg for 2-7 cycles,including 17 patients combined with chemoradiotherapy,13 patients combined with radiotherapy,and 1 patient combined with chemotherapy and immunotherapy.The single dose of radiotherapy was 1.8-2.12 Gy,and the total dose was 50-70 Gy.R language(version 4.2.2)was used to analyze tumor response rate,overall survival,and progression-free survival.Results 31 patients completed the treatment and follow-up,the follow-up time was 2-23 months,the median follow-up time was 11 months.CR(5 cases),PR(13 cases),SD(8 cases),and SD(5 cases)could not be evaluated.ORR was 58.1%.1-year OS was 64%and 1-year PFS was 56%.In the course of treatment,there were 5 cases of grade Ⅲ-Ⅳ hematotoxicity,1 case of grade Ⅲ nausea and 1 case of grade Ⅲ vomiting,all caused by chemotherapy.There were 2 cases of grade Ⅲ oral mucositis and no other serious adverse reactions.Conclusion The addition of nituzumab in the treatment of head and neck squamous cell carcinoma is well tolerated and can improve the sensitivity of chemoradiotherapy and achieve good clinical benefits.
Epidermal growth factor receptorTargeted therapyRadiotherapyChemotherapyHead and neck squamous cell carcinoma
NETL
NSTL
万方数据
